Sort
82,697 grants matching “vaccine development”
Mucosal immunity and heterologous protection induced by single-cycle SIV
$811,508David T Evans · Harvard Medical School · P01 · FY2009 · AI
Institute of Human Virology Clinical Trials Unit
$811,260William Albert Blattner · University Of Maryland Baltimore · U01 · FY2010 · AI
Immune Control and Evasion during Acute HCV Infection
$811,256Georg Michael Lauer · Massachusetts General Hospital · U19 · FY2011 · AI
PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINE
$811,239University Of California Davis · R01 · FY2000 · AI
Immunogen design to enhance the efficacy of Plasmodium vivax vaccine
$811,175Joseph D Smith · Seattle Biomedical Research Institute · R56 · FY2009 · AI
Clinical And Therapeutic Studies Of Human Filariasis and Related Diseases
$811,167Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Small molecule-induced degradation of dengue proteins as an antiviral strategy
$811,132Priscilla Li-Ning Yang · Stanford University · R01 · FY2021 · AI
Effects of obesity on the dynamics of Influenza transmission
$811,115Stacey L Schultz-Cherry · St. Jude Children'S Research Hospital · R01 · FY2022 · AI
UCB/UCSF AIDS International Training and Research Program (AITRP)
$811,071Arthur L. Reingold · University Of California Berkeley · D43 · FY2008 · TW
Assessing functional immunity to influenza infection by quantifying BCR binding avidities
$811,009Steven Carl George · University Of California At Davis · R01 · FY2025 · AI
Immune Responses to VSV/HIV/SIV Hybrids in Macaques
$810,993John Rose · Yale University · R56 · FY2011 · AI
Preclinical Studies and T cell Responses
$810,927Rama Rao Amara · Emory University · U19 · FY2016 · AI
Fine Mechanisms of Adaptive NK Cell Formation Against HIV and SIV
$810,895Roger Keith Reeves · Duke University · R01 · FY2023 · AI
Small molecule-induced degradation of dengue proteins as an antiviral strategy
$810,874Priscilla Li-Ning Yang · Stanford University · R01 · FY2022 · AI
IMPACT OF FARMING ENVIRONMENT ON IMMUNE MATURATION AND RESPIRATORY HEALTH
$810,800James E. Gern · University Of Wisconsin-Madison · U19 · FY2013 · AI
Modeling the Impact of HIV Prevention Interventions
$810,786George R Seage · Harvard School Of Public Health · R01 · FY2010 · MH
Towards a Vaccine to Prevent Toxoplasmosis
$810,759Rima L McLeod · University Of Chicago · U01 · FY2012 · AI
Demystifying the antiviral activity of the IgG3+ antibody response
$810,753Galit Alter · Massachusetts General Hospital · R37 · FY2018 · AI
Zika virus nonstructural protein 5 inhibition of interferon signaling
$810,736Matthew J Evans · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · AI
Host control in Coccidioidomycosis
$810,703University Of Arizona · P01 · FY2005 · AI
Task A05:SMALL ANIMAL MODEL DEVELOPMENT AND UTILIZATION FOR ASPERGILLOSIS
$810,666University Of Texas Hlth Science Center · N01 · FY2013 · AI
Novel Methods to Inform HIV/TB Clinical Trial Development
$810,615Krishna P Reddy · Massachusetts General Hospital · R01 · FY2022 · AI
Inducing durable, protective immune memory against malaria
$810,578Stefan H.i. Kappe · Seattle Children'S Hospital · U01 · FY2020 · AI
Cervical, Anal, and Oral HPV Persistence and Risk Factors Among Adolescent Girls
$810,562Angela Diaz · Icahn School Of Medicine At Mount Sinai · R01 · FY2011 · AI
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: CLINICAL CORE
$810,557Kathleen Neuzil · University Of Maryland Baltimore · N01 · FY2021 · AI